Tocilizumab neutralizes IL-6 activity10, 11 by binding to both the soluble IL-6 receptor (IL-6R) and the membrane bound IL-6R12, and its efficacy for the treatment of RA has been shown in many clinical trials13, 14, 15. Here, IL6R is linked to rheumatoid arthritis.